For the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
For the treatment of chronic inflammatory
demyelinating polyneuropathy (CIDP) in adults
Adjusted INCAT responder rate was 80% at 1 g/kg.
Not actual patient.
Living with CIDP?
Ask your doctor about proven results with PANZYGA
When you have CIDP, it can feel difficult to do the simplest things in life—like brushing your hair, putting on your shoes, and starting your day. PANZYGA is an FDA-approved treatment for CIDP that was shown to be effective in a clinical trial.
Explore these helpful topics to see if PANZYGA may help you on your path to CIDP symptom relief.
Meet Matthew
Hear from Matthew L. about his journey with CIDP and PANZYGA. Learn about the symptoms that changed his life, his road to diagnosis, and the progress he is making today thanks to PANZYGA
Learn more about CIDP
Understand how CIDP affects nerves in the body, and the symptoms you might be experiencing
Get results with PANZYGA
Learn about the clinical study, where patients saw improvement with PANZYGA
Getting started with PANZYGA
View helpful info on what to expect before, during, and after PANZYGA infusions
Find savings and resources
View co-pay program info, where eligible patients may pay as little as $0,* and explore other helpful materials and tools
*Eligible, commercially insured patients may receive a maximum benefit of $12,500 per year or the cost of a patient’s co-pay in a 12-month period (whichever is less) for claims received by the program. No membership fees are required. Federal and state healthcare beneficiaries are not eligible. The PANZYGA Co-Pay Program is good only in the US and Puerto Rico. Terms and conditions/eligibility requirements apply. See full Terms and Conditions on the Financial assistance programs page.
Want support talking to your doctor about PANZYGA?
Download this helpful guide with questions that you can bring to your next appointment
